Overview - PBYI US

Puma Biotechnology Inc

PBYI.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

symbol	last	change	%chng	name	mcap	sector	wiki
PBYI				Puma Biotechnology Inc	0.159B	Healthcare	wiki y

	symbol	prev.close	range	chart	target	percent	period	months	due	rating
B	PBYI	3.02	0,-0.165,0.922,1.256,-0.165	2.32,2.45,2.56,2.56,2.56,2.70,2.86,2.84,2.85,2.98,2.98,2.84,3.20,3.16	2.46-3.20	-6.34%	267,69,267	6.6	Oct 3-Jun 27	56.79%

Intraday chart for PBYI

Please reload the page if latest figures not showing

Key financials

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The arrows show the how the AI thinks the figure affects the stock price (not the change in the figure)

. operatingIncome	22M
. . netInterestIncome	-2M
. incomeBeforeTax	21M
. otherOperatingExpenses	58M
. netIncomeApplicableToCommonShares

. reconciledDepreciation	3M
. netWorkingCapital	46M
. netInvestedCapital	149M
. netDebt	19M
. totalCashFromOperatingActivities	11M
. freeCashFlow. .	11M

News for PBYI

headline news | recent news | latest news | market news

Chart PBYI

Similar stocks g.biopharmaceutical

AbbVie Inc	ABBV	US	Healthcare	17.7343	311317M	-
Amgen Inc	AMGN	US	Healthcare	18.5127	150547M	-
Gilead Sciences Inc	GILD	US	Healthcare	19.4713	116389M	-
Vertex Pharmaceuticals Inc	VRTX	US	Healthcare	23.1724	115983M	-
Regeneron Pharmaceuticals Inc	REGN	US	Healthcare	22.2911	82953M	-
Seagen Inc	SGEN	US	Healthcare	30.4971	43155M	-
Alnylam Pharmaceuticals Inc	ALNY	US	Healthcare	41.8578	32728M	-
Biogen Inc	BIIB	US	Healthcare	21.0542	23290M	-
Illumina Inc	ILMN	US	Healthcare	22.3537	22895M	-
United Therapeutics Corporation	UTHR	US	Healthcare	26.4052	16881M	-

Myshare aims to provide good clear honest and easy analysis of financial markets using a scientific, teaching and informative approach. We try hard but please read our disclaimer. Pages are provided by ourselves and our users. Register to edit pages and see the documentation

Global news | headline news | recent news | latest news | market news | topics | stock topics

News topics and stories from around the world and in the selected country

US News | headline news | recent news | latest news | market news | recent topics | stock topics

News from major news outlets like BBC, CNN and Reuters

Forecasts | Forecast buy | Forecast sell | Forecast up | Forecast down | Forecast sector

Long term stock predictions using AI reading the financial accounts of each company.

``` ``` ``` ```